Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? The effects of concurrent human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection on mortality and patient attrition in those undergoing antiretroviral therapy continue to be a contested area of research. WHAT IS ADDED BY THIS REPORT? According to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, He, Zhu, Qiuying, Huang, Jinghua, Wu, Xiuling, Li, Bo, Liu, Xuanhua, Meng, Qin, Tang, Shuai, Lan, Guanghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023
Materias:
Preplanned Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652092/
https://www.ncbi.nlm.nih.gov/pubmed/38023393
http://dx.doi.org/10.46234/ccdcw2023.183
Descripción
Sumario:WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? The effects of concurrent human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection on mortality and patient attrition in those undergoing antiretroviral therapy continue to be a contested area of research. WHAT IS ADDED BY THIS REPORT? According to the propensity score-matched cohort, individuals with HIV/HCV co-infection exhibit an elevated risk of all-cause mortality [adjusted hazard ratio: 2.048, 95% confidence interval (CI): 1.526–2.749] and attrition (adjusted incidence rate ratio: 1.659, 95% CI: 1.4.8–1.961) compared to their counterparts who are mono-infected with HIV. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? The pressing need for tailored testing and follow-up protocols for individuals co-infected with HIV/HCV cannot be overstated.

Ejemplares similares